alexa BP-C2 improves Functional status, Quality of Life and C
ISSN: 2165-7920

Journal of Clinical Case Reports
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Case Report

BP-C2 improves Functional status, Quality of Life and Corrects Biochemical Imbalances as Adjuvant Therapy to FOLFIRINOX Treatment: A Case of Advanced Inoperable Pancreatic Cancer

Tarek Ibrahim1, Stig Larsen2, Nina Habib Lindkær Jensen3 and Steen Lindkær-Jensen3*
1Department of HPH Surgery, the National Liver Institute, Universityof Menoufiya, Shibin-El-Com, Menoufiya, Egypt
2Department of Veterinary Medicine, Center of Epidemiology and Biostatistics, Norwegian University of Life Science, Olso, Norway
3Department of Surgery and Cancer, Hammersmith Hospital Campus, Imperial College, London, UK
Corresponding Author : Steen Lindkær-Jensen
Department of Surgery and Cancer, The World of Surgery
Block B 1st floor, Hammersmith Hospital Campus
Imperial College, DuCane Road W12 oNN, UK
Tel: +44 20 7589 5111
E-mail: [email protected]
Received March 29, 2015; Accepted April 14, 2015; Published April 17, 2015
Citation: Ibrahim T, Larsen S, HLindkær Jensen N, Lindkær-Jensen S (2015) BPC2 improves Functional status, Quality of Life and Corrects Biochemical Imbalances as Adjuvant Therapy to FOLFIRINOX Treatment: A Case of Advanced Inoperable Pancreatic Cancer. J Clin Case Rep 5:514. doi:10.4172/2165-7920.1000514
Copyright: © 2015 Ibrahim T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


A successful example of use of a new regenerative substance BP-C2 in a patient with advanced inoperable pancreatic cancer before, during and after chemotherapy is described. The patient was subjected regularly to medical history review, physical examination, serum biochemistry, complete blood picture, computed tomography of the abdomen, and Quality-of-Life questionnaires (QoL). BP-C2 treatment was started and subsequently the condition of the patient improved. During this 26 weeks long treatment period, the patient tolerated FOLFIRINOX treatment well without any adverse effects (AE) and with improvement of her functional status. During the treatment with FOLFIRINOX and BP-C2 the sum diameter of the target lesions was reduced by 34.8%, the sum of non-target lesions were reduced by 86.2% and the number of non-target lesions fell from 4 to 1 and the AEs disappeared. C - reactive protein (CRP) was normalized and CA 19-9 reduced by 88% from baseline. QoL variables improved substantially. No neutropenia was observed after week 18 and all biochemical parameters were normalized at week 25. After discontinuation of BP-C2, recurrence of the tumors and AEs occurred A 19-9 and as well as QoL variables returned to baseline level. BP-C2 is a promising adjuvant treatment to the toxic chemotherapy regimens used in inoperable pancreatic cancer patients.

Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version